Acta Dermato Venereologica · 2010 · 31 citations · 29 references
MedicineDermatologyPathologyDermatopathologyHistopathologyMolecular PathologyEpidermolysis BullosaInflammatory Skin DiseasesInflammatory Skin DisordersSkin RegenerationBullous DermatosesCol7a1 MutationsDystrophic Epidermolysis BullosaEpidermolysis Bullosa SyndromesImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingSkin Disease Genetics
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited skin disorder caused by mutations in the COL7A1 gene, which encodes collagen VII (COL7). Skin ulcers in RDEB patients are sometimes slow to heal. We describe here the therapeutic response of intractable skin ulcers in two patients with generalized RDEB to treatment with an allogeneic cultured dermal substitute (CDS). Skin ulcers in both patients epithelialized by 3-4 weeks after this treatment. Immunohistochemical studies demonstrated that the COL7 expression level remained reduced with respect to the control skin and that it did not differ significantly between graft-treated and untreated areas. Electron microscopy showed aberrant anchoring fibrils beneath the lamina densa of both specimens. In conclusion, CDS is a promising modality for treatment of intractable skin ulcers in patients with RDEB, even though it does not appear to increase COL7 expression.
29
Jo‐David Fine, Robin A.J. Eady, Eugene A. Bauer et al. · Journal of the American Academy of Dermatology · 2008 · 933 citations
Medicine, Dermatology, Pathology +6
Potential of Fibroblast Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa
Tracy Wong, Luke Gammon, Lu Liu et al. · Journal of Investigative Dermatology · 2008 · 249 citations · Full text